A review of adjuvants for Leishmania vaccine candidates

Kimutai, 2009, Leishmaniasis in Northern and western Africa: A review, Afr J Infect Dis, 3, 14 World Health Organization. Control of Leishmaniasis. Report by the Secretariat; Sixth World Health Assembly 2007; A60/10 Provisional agenta item 12.3. Ngure, 2009, A review of leishmaniasis in Eastern Africa, JNMU, 23, 79 Handman, 2001, Leishmaniasis. Current status of vaccine development, Clin Microbiol Rev, 14, 229, 10.1128/CMR.14.2.229-243.2001 Tripathi, 2007, Immune response to Leishmania: paradox rather than paradigm, Immunol Med Microbiol, 51, 229, 10.1111/j.1574-695X.2007.00311.x Masina, 2003, Protection against cutaneous leishmaniasis in outbred vervet monkeys, using a recombinant histone H–1 antigen, J Infect Dis, 188, 1250, 10.1086/378677 Reed, 2009, New horizons in adjuvants for vaccine development, Trends Immunol, 30, 23, 10.1016/j.it.2008.09.006 Saha, 2006, Immune responses in kala–azar, Indian J Med Res, 123, 245 Tripathi, 2008, Prophylactic efficacy of high–molecular–weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis, Scand J Immunol, 68, 492, 10.1111/j.1365-3083.2008.02171.x Kenney, 1999, Protective immunity using recombinant human IL–12 and alum as adjuvants in a primate model of cutaneous leishmaniasis, J Immunol, 163, 4481, 10.4049/jimmunol.163.8.4481 Sohrabi, 2005, Evaluation of immune response against leishmaniasis in resistance C57 BL/6 mice immunized with liposomes containing autoclaved Leishmania major with BCG, Cell Mol Biol Lett, 10, S98 Chedid, 1985, Adjuvants of immunity, Ann I'Institut Pasteur Immunol, 136D, 283, 10.1016/S0769-2625(85)80113-6 Mayrink, 1979, A field trial of a vaccine against American dermal leishmaniasis, Trans Roy Soc Trop Med Hyg, 73, 385, 10.1016/0035-9203(79)90159-7 Afonso, 1994, The adjuvant effect of interleukin–12 in a vaccine against Leishmania major, Science, 263, 235, 10.1126/science.7904381 Gicheru, 2001, Vervet monkeys vaccinated with killed Leishmania major parasites and Interleukin–12 develop a type 1 immune response but are not protected against challenge infection, Infect Immun, 69, 245, 10.1128/IAI.69.1.245-251.2001 D'Andrea, 1992, Production of NK cell stimulatory factor (interleukin–12) by peripheral blood mononuclear cells, J Exp Med, 176, 1387, 10.1084/jem.176.5.1387 Trinchieri, 1993, Interleukin–12 and its role in the generation of TH1 cells, Immun Today, 14, 335, 10.1016/0167-5699(93)90230-I Liew, 1993, Immunology of leishmaniasis, Adv Parasitol, 32, 161, 10.1016/S0065-308X(08)60208-0 Hsieh, 1993, Development of Th1 CD41 T cells through IL–12 produced by Listeria–induced macrophages, Science, 260, 547, 10.1126/science.8097338 Scott, 1993, IL–12: initiation cytokine for cell–mediated immunity, Science, 260, 496, 10.1126/science.8097337 Scott, 1988, Immunoregulation of cutaneous leishmaniasis: T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens, J Exp Med, 168, 1675, 10.1084/jem.168.5.1675 Skeiky, 2002, Protective efficacy of a tandemly linked, multi–subunit recombinant leishmanial vaccine (Leish–111f) formulated in MPL adjuvant, Vaccine, 20, 3292, 10.1016/S0264-410X(02)00302-X Romani, 1994, Interleukin–12 but not IFN–g production correlates with induction of T helper type–1 phenotype in murine candidiasis, Eur J Immunol, 24, 909, 10.1002/eji.1830240419 Badaro, 2001, Successful use of a defined antigen/GM–CSF adjuvant vaccine to treat mucosal leishmaniasis refractory to antimony: A case report, Braz J Infect Dis, 5, 223, 10.1590/S1413-86702001000400008 Lin, 1997, Vaccine adjuvants: A new hope for effective immunizations, Braz J Infect Dis, 1, 106 Badaro, 1994, Recombinant human granulocyte–macrophage colony–stimulating factor reverses neutropenia and reduces secondary infections in visceral, J Infect Dis, 170, 413, 10.1093/infdis/170.2.413 Herwaldt, 1999, Leishmaniasis, Lancet, 354, 1191, 10.1016/S0140-6736(98)10178-2 Tokunga, 1999, How BCG led to the discovery of immunostimulatory DNA, Jap J Infect Dis, 52, 1, 10.7883/yoken.52.1 Abdelhak, 1995, Recombinant BCG expressing the leishmania surface antigen Gp63 induces protective immunity against Leishmania major infection in BALB/c mice, Microbiol, 141, 1585, 10.1099/13500872-141-7-1585 Aebischer, 2000, Subunit vaccination of mice against new world cutaneous leishmaniasis: comparison of three proteins expressed in amastigotes and six adjuvants, Infect Immun, 68, 1328, 10.1128/IAI.68.3.1328-1336.2000 Castes, 1989, Cell–mediated immunity in localized cutaneous leishmaniasis patients before and after treatment with immunotherapy or chemotherapy, Parasit Immunol, 11, 211, 10.1111/j.1365-3024.1989.tb00660.x Cabrera, 2000, Immunotherapy with live BCG plus heat killed Leishmania induces a T helper 1–like response in American cutaneous leishmaniasis patients, Parasit Immunol, 22, 73, 10.1046/j.1365-3024.2000.00278.x Arjo, 1999, Vaccination of mice with a combination of BCG and killed Leishmania promastigotes reduces acute Trypanosoma cruzi infection by promoting an IFN–gamma response, Vaccine, 17, 957, 10.1016/S0264-410X(98)00311-9 Misra, 2001, Successful vaccination against Leishmania donovani infection in Indian langur using alum–precipitated autoclaved Leishmania major with BCG, Vaccine, 19, 3485, 10.1016/S0264-410X(01)00058-5 Momeni, 1998, A randomised, double–blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran, Vaccine, 17, 466, 10.1016/S0264-410X(98)00220-5 Shoenfeld, 1988, Mycobacteria and autoimmunity, Immunol Today, 9, 178, 10.1016/0167-5699(88)91294-7 Simila, 1988, Sternal abscess as a complication of BCG–revaccination, Tubercle, 69, 67, 10.1016/0041-3879(88)90043-8 Milstien, 1990, Quality control of BCG vaccine by WHO: a review of factors that may influence vaccine effectiveness and safety, WHO Bulletin OMS, 68, 93 Toledo, 2001, A phase I clinical trial of a multi–epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non–HIV–1 infected human volunteers, Vaccine, 19, 4328, 10.1016/S0264-410X(01)00111-6 Oliveira, 2005, Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant montanide ISA 720 in a phase I trial, Infect Immun, 73, 3585, 10.1128/IAI.73.6.3587-3597.2005 Collins, 2006, Assessment of transmission–blocking activity of candidate pvs25 vaccine using gametocytes from chimpanzees, A J Trop Med Hyg, 74, 215, 10.4269/ajtmh.2006.74.215 Smrkovski, 1977, Effect of treatment with BCG on the course of visceral leishmaniasis in BALB/c mice, Infect Immun, 16, 249, 10.1128/IAI.16.1.249-257.1977 Sharples, 1994, Immune response in healthy volunteers vaccinated with BCG plus killed Leishmania promastigotes: antibody responses to mycobacterial and leishmanial antigens, Vaccine, 12, 1402, 10.1016/0264-410X(94)90149-X Tonui, 2004, Immunization with Leishmania major exogenous antigens protects susceptible BALB/c mice against challenge infection with Leishmania major, Infect Immun, 72, 5654, 10.1128/IAI.72.10.5654-5661.2004 Kaslow, 1994, Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum, Infect Immun, 62, 5576, 10.1128/IAI.62.12.5576-5580.1994 Scheibner, 2000, Adverse effects of adjuvants in vaccines, Exper Molecul Pathol, 8, 1 Glenny, 1931, Rate of disappearance of diphtheria toxoid injected into rabbits and guinea pigs: toxoid precipitated with alum, J Pathol Bacteriol, 34, 267, 10.1002/path.1700340214 Eickhoff, 2002, Workshop summary: Aluminium in vaccines, Vaccine, 20, S1, 10.1016/S0264-410X(02)00163-9 Lindblad, 2004, Aluminium adjuvants–in retrospect and prospect, Vaccine, 22, 3658, 10.1016/j.vaccine.2004.03.032 Gurunathan, 1998, Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection, Nat Med, 4, 1409, 10.1038/4000 Gupta, 1995, Adjuvant properties of aluminium and calcium compounds, 229 Coler, 2005, Second–generation vaccines against leishmaniasis, Trends Parasitol, 21, 244, 10.1016/j.pt.2005.03.006 Coler, 2007, Leish–111f, a recombinant polyprotein vaccine that protects against visceral leishmaniasis by elicitation of CD4+ T cells, Infect Immun, 75, 4648, 10.1128/IAI.00394-07 Kumar, 2004, CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine, Infect Immun, 72, 949, 10.1128/IAI.72.2.949-957.2004 Verthelyi, 2002, CpG oligodeoxynucleotides as vaccine adjuvants in primates, J Immunol, 168, 1659, 10.4049/jimmunol.168.4.1659 Stacey, 1999, Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major, Infect Immun, 67, 3719, 10.1128/IAI.67.8.3719-3726.1999 Kahl, 1989, Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. Optimization and assessment of the requirement for intravenous immunization, J Immunol, 142, 4441, 10.4049/jimmunol.142.12.4441 Afrin, 1997, Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes, Infect Immun, 65, 2371, 10.1128/IAI.65.6.2371-2377.1997 Holbrook, 1981, Immunization against Leishmania donovani: Glucan as an adjuvant with killed promastigotes, Am J Trop Med Hyg, 30, 762, 10.4269/ajtmh.1981.30.762 Holbrook, 1983, Immunization of mice against Leishmania donovani by subcutaneous injections of dead promastigotes, Am J Trop Med Hyg, 32, 51, 10.4269/ajtmh.1983.32.51 Cook, 1983, Immunogenicity of soluble and particulate antigens from Leishmania donovani: Effect of glucan as an adjuvant, Infect Immun, 40, 1038, 10.1128/IAI.40.3.1038-1043.1983 Champsi, 1988, Membrane glycoprotein M–2 protects against Leishmania amazonensis infection, Infect Immun, 56, 3272, 10.1128/IAI.56.12.3272-3279.1988 Handman, 1995, Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by TH1 type of immune response, Infect Immun, 63, 4261, 10.1128/IAI.63.11.4261-4267.1995 Sjorlander, 1998, Vaccination with recombinant parasite surface antigen 2 from Leishmania major induces a Th 1 type of immune response but does not protect against infection, Vaccine, 16, 2077, 10.1016/S0264-410X(98)00075-9 de Carvalho Vilela, 2007, Successful vaccination against Leishmania chagasi infection in BALB/c mice with freeze–thaw Leishmania antigen and Corynabacterium parvum, Act Trop, 104, 133, 10.1016/j.actatropica.2007.08.007 Kensil, 1995, Structural and immunological characterization of the vaccine adjuvant QS–21, Pharm Biotechnol, 6, 525, 10.1007/978-1-4615-1823-5_22 Giunchetti, 2007, Immunogenicity of a killed Leishmania vaccine with saponin adjuvant in dogs, Vaccine, 25, 7674, 10.1016/j.vaccine.2007.08.009 Santos, 1999, Vaccination of Swiss albino mice against experimental visceral leishmaniasis with the FML antigen of Leishmania donovani, Vaccine, 17, 2554, 10.1016/S0264-410X(99)00058-4 Osebold, 1992, Mechanism of action by immunologic adjuvants, J Am Vet Med Assoc, 181, 983 Panaro, 2001, Nitric oxide production by macrophages of dogs vaccinated with killed Leishmania infantum promastigotes, Comp Immunol, Microbiol Infect Dis, 24, 187, 10.1016/S0147-9571(00)00026-6 Rivier, 1999, Vaccination against Leishmania major in a CBA mouse model of infection: role of adjuvants and mechanism of protection, Parasit Immunol, 21, 461, 10.1046/j.1365-3024.1999.00244.x